145 related articles for article (PubMed ID: 31199148)
1. Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
Lin J; Lu W; Caravella JA; Campbell AM; Diebold RB; Ericsson A; Fritzen E; Gustafson GR; Lancia DR; Shelekhin T; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Diep H; Kershaw M; Yao L; Kauffman G; Hubbs SE; Luke GP; Toms AV; Wang L; Bair KW; Barr KJ; Dinsmore C; Walker D; Ashwell S
J Med Chem; 2019 Jul; 62(14):6575-6596. PubMed ID: 31199148
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
Ma T; Zou F; Pusch S; Xu Y; von Deimling A; Zha X
J Med Chem; 2018 Oct; 61(20):8981-9003. PubMed ID: 29847930
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Ma R; Yun CH
Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.
Zou F; Pusch S; Hua J; Ma T; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
Bioorg Med Chem Lett; 2018 Feb; 28(3):388-393. PubMed ID: 29290542
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.
Caravella JA; Lin J; Diebold RB; Campbell AM; Ericsson A; Gustafson G; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Kershaw M; Yao L; Toms AV; Barr KJ; Dinsmore CJ; Walker D; Ashwell S; Lu W
J Med Chem; 2020 Feb; 63(4):1612-1623. PubMed ID: 31971798
[TBL] [Abstract][Full Text] [Related]
7. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
Okoye-Okafor UC; Bartholdy B; Cartier J; Gao EN; Pietrak B; Rendina AR; Rominger C; Quinn C; Smallwood A; Wiggall KJ; Reif AJ; Schmidt SJ; Qi H; Zhao H; Joberty G; Faelth-Savitski M; Bantscheff M; Drewes G; Duraiswami C; Brady P; Groy A; Narayanagari SR; Antony-Debre I; Mitchell K; Wang HR; Kao YR; Christopeit M; Carvajal L; Barreyro L; Paietta E; Makishima H; Will B; Concha N; Adams ND; Schwartz B; McCabe MT; Maciejewski J; Verma A; Steidl U
Nat Chem Biol; 2015 Nov; 11(11):878-86. PubMed ID: 26436839
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule.
Deng G; Shen J; Yin M; McManus J; Mathieu M; Gee P; He T; Shi C; Bedel O; McLean LR; Le-Strat F; Zhang Y; Marquette JP; Gao Q; Zhang B; Rak A; Hoffmann D; Rooney E; Vassort A; Englaro W; Li Y; Patel V; Adrian F; Gross S; Wiederschain D; Cheng H; Licht S
J Biol Chem; 2015 Jan; 290(2):762-74. PubMed ID: 25391653
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
Ma T; Zou F; Pusch S; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
Bioorg Med Chem; 2017 Dec; 25(24):6379-6387. PubMed ID: 29089260
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells.
Jones S; Ahmet J; Ayton K; Ball M; Cockerill M; Fairweather E; Hamilton N; Harper P; Hitchin J; Jordan A; Levy C; Lopez R; McKenzie E; Packer M; Plant D; Simpson I; Simpson P; Sinclair I; Somervaille TC; Small H; Spencer GJ; Thomson G; Tonge M; Waddell I; Walsh J; Waszkowycz B; Wigglesworth M; Wiseman DH; Ogilvie D
J Med Chem; 2016 Dec; 59(24):11120-11137. PubMed ID: 28002956
[TBL] [Abstract][Full Text] [Related]
11. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
[TBL] [Abstract][Full Text] [Related]
12. Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
Zheng Q; Tang S; Fu X; Chen Z; Ye Y; Lan X; Jiang L; Huang Y; Ding J; Geng M; Huang M; Wan H
Bioorg Med Chem Lett; 2017 Dec; 27(23):5262-5266. PubMed ID: 29079473
[TBL] [Abstract][Full Text] [Related]
13. Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.
Urban DJ; Martinez NJ; Davis MI; Brimacombe KR; Cheff DM; Lee TD; Henderson MJ; Titus SA; Pragani R; Rohde JM; Liu L; Fang Y; Karavadhi S; Shah P; Lee OW; Wang A; McIver A; Zheng H; Wang X; Xu X; Jadhav A; Simeonov A; Shen M; Boxer MB; Hall MD
Sci Rep; 2017 Oct; 7(1):12758. PubMed ID: 28986582
[TBL] [Abstract][Full Text] [Related]
14. Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity.
Xie X; Baird D; Bowen K; Capka V; Chen J; Chenail G; Cho Y; Dooley J; Farsidjani A; Fortin P; Kohls D; Kulathila R; Lin F; McKay D; Rodrigues L; Sage D; Touré BB; van der Plas S; Wright K; Xu M; Yin H; Levell J; Pagliarini RA
Structure; 2017 Mar; 25(3):506-513. PubMed ID: 28132785
[TBL] [Abstract][Full Text] [Related]
15. Discovery and Optimization of 2
Rohde JM; Karavadhi S; Pragani R; Liu L; Fang Y; Zhang W; McIver A; Zheng H; Liu Q; Davis MI; Urban DJ; Lee TD; Cheff DM; Hollingshead M; Henderson MJ; Martinez NJ; Brimacombe KR; Yasgar A; Zhao W; Klumpp-Thomas C; Michael S; Covey J; Moore WJ; Stott GM; Li Z; Simeonov A; Jadhav A; Frye S; Hall MD; Shen M; Wang X; Patnaik S; Boxer MB
J Med Chem; 2021 Apr; 64(8):4913-4946. PubMed ID: 33822623
[TBL] [Abstract][Full Text] [Related]
16. Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor.
Liang Q; Wang B; Zou F; Guo G; Wang W; Wang W; Liu Q; Shen L; Hu C; Wang W; Wang A; Huang T; He Y; Xia R; Ge J; Liu J; Liu Q
Eur J Med Chem; 2023 Aug; 256():115411. PubMed ID: 37209613
[TBL] [Abstract][Full Text] [Related]
17. Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
Zheng Q; Chen Z; Wan H; Tang S; Ye Y; Xu Y; Jiang L; Ding J; Geng M; Huang M; Huang Y
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3808-3812. PubMed ID: 30413349
[TBL] [Abstract][Full Text] [Related]
18. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Rohle D; Popovici-Muller J; Palaskas N; Turcan S; Grommes C; Campos C; Tsoi J; Clark O; Oldrini B; Komisopoulou E; Kunii K; Pedraza A; Schalm S; Silverman L; Miller A; Wang F; Yang H; Chen Y; Kernytsky A; Rosenblum MK; Liu W; Biller SA; Su SM; Brennan CW; Chan TA; Graeber TG; Yen KE; Mellinghoff IK
Science; 2013 May; 340(6132):626-30. PubMed ID: 23558169
[TBL] [Abstract][Full Text] [Related]
19. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J
Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044
[TBL] [Abstract][Full Text] [Related]
20. Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening.
Duan Z; Liu J; Niu L; Wang J; Feng M; Chen H; Luo C
Bioorg Med Chem; 2019 Aug; 27(15):3229-3236. PubMed ID: 31208797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
